KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Accumulated Expenses for 13 consecutive years, with $38.2 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses changed N/A to $38.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $38.2 million for FY2025, N/A changed from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $38.2 million at Supernus Pharmaceuticals, up from $26.3 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $38.2 million in Q4 2025, with the low at $710000.0 in Q3 2023.
  • Average Other Accumulated Expenses over 5 years is $12.2 million, with a median of $8.2 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses crashed 91.33% in 2023, then surged 664.7% in 2025.
  • Over 5 years, Other Accumulated Expenses stood at $20.1 million in 2021, then decreased by 16.24% to $16.9 million in 2022, then tumbled by 74.6% to $4.3 million in 2023, then decreased by 15.41% to $3.6 million in 2024, then skyrocketed by 954.98% to $38.2 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $38.2 million, $26.3 million, and $27.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.